key: cord-0821082-7z2jsu12
authors: Blauvelt, Andrew; Ehst, Benjamin D.
title: Do IL-17 Inhibitors Increase Risk of Respiratory Tract Infections?
date: 2020-07-01
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.1000
sha: 2422517e1d5102be48745c72b48f42f20c15f507
doc_id: 821082
cord_uid: 7z2jsu12

nan

Pharma, and UCB Pharma, and as a paid speaker for Eli Lilly and Company, Novartis, Ortho, Regeneron, and Sanofi Genzyme.

In a recent meta-estimate, Gelfand and colleagues conclude that psoriasis patients on IL-17 blockers are possibly at increased risk of respiratory tract infections (RTIs). 1 We agree with the need and wisdom to better understand the infectious risk that these medications pose, however, we take issue with the manner in which the data were derived and how the discussion was framed, especially during the COVID-19 pandemic.

The meta-analysis grouped psoriasis patients receiving three medications: secukinumab, ixekizumab, and brodalumab. The first two drugs block IL-17A, whereas brodalumab blocks IL-17RA, a subunit of the IL-17 receptor (blocking signaling by IL-17A, IL-17C, IL-17-E, and IL-17F). 2 As brodalumab has a broader mechanism of action than secukinumab/ixekizumab, its use in psoriasis patients may lead to differential infectious consequences. When running the meta-estimates in two treatment groups (patients on secukinumab/ixekizumab vs. those on brodalumab), were there significantly more RTIs in either group compared to patients on placebo?

Second, it is well-established that IL-17 inhibition predisposes to mucocutaneous candidiasis. 5 Some of the adverse event terms used to collect "RTI" cases by Wan et al, e.g., oropharyngeal pain, may in fact be manifestations of thrush, and have no relationship to viral infections like COVID-19. Importantly, the authors acknowledge this limitation of their article by saying "Sensitivity analyses varying the terms analyzed yielded similar findings but with loss of statistical significance." This critical sentence seems to be lost in the overall message that points to a "potential signal" between IL-17 inhibitors and risk of RTIs. We believe the data suggest that IL-17 inhibitors are unlikely to be associated with increased risk of RTIs.

Third, it is assumed that the reporting of adverse events, including RTIs, in placebocontrolled psoriasis trials is equal in study subjects on placebo vs. those on active drug.

Since treatment effects with IL-17 inhibitors are so large and occur so early, with investigators and patients often correctly guessing what treatment arm they have been placed on, there may be both patient and investigator bias to report more adverse events when patients are on active drug. 3 Possible reporting bias may skew results towards a positive safety signal that may not otherwise be detected.

Fourth, the authors start their discussion by speaking of biologics as a class of drugs, which they are not, lumping them together as "immunosuppressives." A "biologic" is simply a drug that is manufactured through biological means, rather than through chemical processes. Each biologic class has distinct mechanisms of action and unique safety profiles. Correct use of terms surrounding biologics discourages misplaced "fear of biologics," which is widely prevalent among misinformed psoriasis patients and practitioners. 4 Data analyses related to COVID-19 need not unnecessarily be couched in overall ominous terms.

Lastly, one should consider whether the results from this meta-estimate "fit" with realworld use of IL-17 inhibitors. It has been our collective 10+-year experience of treating hundreds of psoriasis patients with IL-17 inhibitors, in both clinical trials and clinical practices, that they are not at increased risk for RTIs. More meticulous evaluation is needed on this topic.

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings

Causes of reporting bias: a theoretical framework

Essential truths for the care and management of moderate-to-severe psoriasis

Interleukin-23/interleukin-17A dysfunction phenotypes inform possible clinical effects from anti-interleukin-17A therapies